跳至主要内容
临床试验/NCT00129818
NCT00129818已完成4 期

A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding

Novartis14 个研究点 分布在 1 个国家开始时间: 2004年7月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Novartis
试验地点
14
主要终点
Group 1. Reduction of HSV DNA PCR positive days in HSV-2 seropositive patients with a history of clinical genital herpes lesions

研究概览

简要总结

The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males or non-pregnant females at least 18 years of age with HSV-2 seropositive serology with or without history of clinically diagnosed recurrent genital herpes

排除标准

  • Pregnancy
  • History of renal dysfunction
  • Use of immunosuppressive therapy, including steroids (other than topical or inhaled), or use of probenecid
  • Hypersensitivity to famciclovir, valacyclovir or drugs with similar chemical structure

结局指标

主要结局

Group 1. Reduction of HSV DNA PCR positive days in HSV-2 seropositive patients with a history of clinical genital herpes lesions

Group 2. Reduction of HSV DNA PCR positive days in HSV-2 seropositive patients without a history of clinical genital herpes lesions

次要结局

  • reduction of HSV DNA PCR positive days without lesions in HSV-2 seropositive patients with and without a history of clinical genital herpes lesions
  • quantitative HSV DNA PCR, during the days with positive HSV-2 shedding.
  • time to the first recurrence of genital herpes and number of genital herpes recurrence episodes
  • oral HSV-1 and/or HSV-2 shedding in HSV-1 and HSV-2 seropositive patients
  • reduction of HSV DNA PCR positive days with lesions in HSV-2 seropositive patients with and without a history of clinical genital herpes lesions

研究者

发起方
Novartis
申办方类型
Industry

研究点 (14)

Loading locations...

相似试验